Control Bionics Ltd. (AU:CBL) has released an update.
Control Bionics Ltd. reports significant advancements, including the TGA approval of its DROVE wheelchair module and a strong financial quarter with a 14% increase in US sales and a record month in June. The company also highlights strategic partnerships in Japan and the US, and expects future growth with the innovative NeuroStrip technology trials and pending US Medicare approval for the NeuroNode. Despite delays in Australian NDIS approvals, a 20% increase in orders indicates positive momentum heading into FY25.
For further insights into AU:CBL stock, check out TipRanks’ Stock Analysis page.
